JP2009525323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525323A5 JP2009525323A5 JP2008553193A JP2008553193A JP2009525323A5 JP 2009525323 A5 JP2009525323 A5 JP 2009525323A5 JP 2008553193 A JP2008553193 A JP 2008553193A JP 2008553193 A JP2008553193 A JP 2008553193A JP 2009525323 A5 JP2009525323 A5 JP 2009525323A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- sequence
- stathmin
- tlr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 102000008230 Toll-like receptor 3 Human genes 0.000 claims 15
- 108010060885 Toll-like receptor 3 Proteins 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000002243 precursor Substances 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 101000697502 Homo sapiens Stathmin-3 Proteins 0.000 claims 4
- 102100028052 Stathmin-3 Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000005465 Stathmin Human genes 0.000 claims 3
- 108050003387 Stathmin Proteins 0.000 claims 3
- 230000003412 degenerative effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000025535 REM sleep behavior disease Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 239000004135 Bone phosphate Substances 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 101000697510 Homo sapiens Stathmin-2 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 102100028051 Stathmin-2 Human genes 0.000 claims 1
- 102000019355 Synuclein Human genes 0.000 claims 1
- 108050006783 Synuclein Proteins 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 206010044541 Traumatic shock Diseases 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06075265A EP1815863A1 (en) | 2006-02-03 | 2006-02-03 | Use of TLR3 agonists for the treatment of neurodegenerative disorders |
| PCT/NL2007/050045 WO2007089151A1 (en) | 2006-02-03 | 2007-02-02 | Use of tlr3 agonists for the treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009525323A JP2009525323A (ja) | 2009-07-09 |
| JP2009525323A5 true JP2009525323A5 (enExample) | 2010-03-25 |
Family
ID=36087734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553193A Pending JP2009525323A (ja) | 2006-02-03 | 2007-02-02 | 神経変性疾患の処置の為にｔｌｒ３アゴニストを使用する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090253622A1 (enExample) |
| EP (2) | EP1815863A1 (enExample) |
| JP (1) | JP2009525323A (enExample) |
| AU (1) | AU2007210379A1 (enExample) |
| WO (1) | WO2007089151A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100130425A1 (en) * | 2005-09-09 | 2010-05-27 | Oregon Health & Science University | Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia |
| US9003695B2 (en) | 2006-12-29 | 2015-04-14 | Genifuel Corporation | Controlled growth environments for algae cultivation |
| GB201022049D0 (en) * | 2010-12-29 | 2011-02-02 | Imp Innovations Ltd | Methods |
| EP2687224A1 (en) * | 2012-07-19 | 2014-01-22 | Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH | Medicament for wound treatment |
| US10421971B2 (en) | 2014-01-15 | 2019-09-24 | The University Of Chicago | Anti-tumor therapy |
| US10105305B2 (en) * | 2014-02-19 | 2018-10-23 | The Johns Hopkins University | Compositions and methods for promoting skin regeneration and hair growth |
| EP3298131B1 (en) | 2015-05-20 | 2023-04-26 | The Regents of The University of California | Method for generating human dendritic cells for immunotherapy |
| MX2018005274A (es) | 2015-10-30 | 2019-09-19 | The Regents Of The Universtiy Of California | Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. |
| EP3318270A1 (en) | 2016-11-08 | 2018-05-09 | RMB-Research GmbH | Stathmin composition and method for treating wounds |
| CN110177887B (zh) | 2016-11-10 | 2024-10-29 | 达丽斯生物医学公司 | 用于扩增和检测沙眼衣原体的多核苷酸 |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3046019A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| US10450616B1 (en) | 2018-05-09 | 2019-10-22 | Talis Biomedical Corporation | Polynucleotides for the amplification and detection of Chlamydia trachomatis |
| CN114173821A (zh) * | 2019-01-14 | 2022-03-11 | 哈佛学院校长同事会 | 用于恢复stmn2水平的方法和组合物 |
| WO2020232226A1 (en) | 2019-05-16 | 2020-11-19 | The Johns Hopkins University | Compositions and methods for skin rejuvenation |
| JP7795914B2 (ja) * | 2019-06-03 | 2026-01-08 | クラリス コーポレーション | 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法 |
| WO2021076964A1 (en) * | 2019-10-17 | 2021-04-22 | Icahn School Of Medicine At Mount Sinai | Stathmin 2 (stmn2) as a therapeutic target for parkinson's disease |
| US11891662B2 (en) * | 2019-12-02 | 2024-02-06 | Talis Biomedical Corporation | Polynucleotides for amplification and detection of human beta actin |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| US11047007B1 (en) | 2020-03-23 | 2021-06-29 | Talis Biomedical Corporation | Polynucleotides for amplification and detection of SARS-CoV-2 |
| US12616692B2 (en) | 2020-07-02 | 2026-05-05 | ViiV Healthcare Company; and | Method of achieving HIV viral remission using long-acting antiretroviral agents |
| CN117320722A (zh) | 2021-04-28 | 2023-12-29 | 埃尼奥制药公司 | 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044935A1 (en) * | 1997-06-11 | 2003-03-06 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
| EP1242443A4 (en) * | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| WO2002044424A1 (en) * | 2000-12-01 | 2002-06-06 | Board Of Trustees Of The University Of Arkansas | Compositions, methods, apparatus and products comprising a stathmin/oncoprotein 18 sequence for detecting and treating cancer |
| EP1288226A1 (en) * | 2001-09-03 | 2003-03-05 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system |
| JP2011516026A (ja) * | 2002-11-26 | 2011-05-26 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| WO2004078925A2 (en) * | 2003-02-28 | 2004-09-16 | Irm Llc | Methods and compositions for treating and preventing neurodegenerative diseases |
| AU2005238446B2 (en) * | 2004-04-15 | 2009-07-30 | Banyan Biomarkers Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
-
2006
- 2006-02-03 EP EP06075265A patent/EP1815863A1/en not_active Withdrawn
-
2007
- 2007-02-02 AU AU2007210379A patent/AU2007210379A1/en not_active Abandoned
- 2007-02-02 US US12/162,916 patent/US20090253622A1/en not_active Abandoned
- 2007-02-02 JP JP2008553193A patent/JP2009525323A/ja active Pending
- 2007-02-02 WO PCT/NL2007/050045 patent/WO2007089151A1/en not_active Ceased
- 2007-02-02 EP EP07715865A patent/EP1991251A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Dental stem cell-derived extracellular vesicles as promising therapeutic agents in the treatment of diseases | |
| MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
| MXPA05011524A (es) | Acidos carboxilicos sustituidos. | |
| MXPA05010937A (es) | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. | |
| UA96441C2 (ru) | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением | |
| MX2009004467A (es) | Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk). | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| MX2009007136A (es) | Metodos para suministrar moleculas y objetivos de enlace especificos de enfermedades. | |
| EP4342992A3 (en) | Gene therapy for neurodegenerative disorders | |
| TN2013000285A1 (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | |
| EA200700212A1 (ru) | Многовалентные vla-4 антагонисты, содержащие полимерные фрагменты | |
| MY162502A (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| EP4552692A3 (en) | Cns gene delivery using peripheral administration of aav vectors | |
| TW200630327A (en) | Substituted phenylalkanoic acids | |
| EA201200002A1 (ru) | Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний | |
| MXPA05011539A (es) | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. | |
| MXPA05010293A (es) | 4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas. | |
| JP2012508254A (ja) | α７選択的リガンドを用いる治療 | |
| EA200800975A1 (ru) | ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ | |
| WO2011056477A3 (en) | Methods for treating inflammation and oxidative stress related diseases | |
| NZ610689A (en) | Substituted 6-amino-nicotinamides as kcnq2/3 modulators | |
| ATE500265T1 (de) | Synthetische mecp2-sequenz für die proteinersatztherapie | |
| TW200630354A (en) | Substituted amino carboxylic acids | |
| WO2008135661A3 (fr) | Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines | |
| FR2918282B1 (fr) | Medicament pour le traitement de la maladie de parkinson |